The Annual Meeting of the American Society of Hematology (ASH), convened in December 2014, highlighted the expanding array of novel therapy treatments showing promise for non-Hodgkin lymphoma (NHL) patients. Covering a gamut of research from expanded analyses of recently approved…
The Annual Meeting of the American Society of Hematology (ASH), convened in December 2014, highlighted the expanding array of novel therapy treatments showing promise for non-Hodgkin lymphoma (NHL) patients. Covering a gamut of research from expanded analyses of recently approved…
Though much of the lymphoma research presented at the Annual Meeting of the American Society of Hematology (ASH) in December 2014 focused on the growing number of novel therapies for this disease, a subset of presentations focused on the impact…
Though much of the lymphoma research presented at the Annual Meeting of the American Society of Hematology (ASH) in December 2014 focused on the growing number of novel therapies for this disease, a subset of presentations focused on the impact…
Double hit lymphoma (DHL) describes patients whose lymphoma tumors exhibit mutations on two significant genes, where most lymphoma patients have a mutation on only one. Currently found primarily in diffuse large B-cell lymphoma (DLBCL), DHL patients often respond poorly to…
Among the many exciting clinical trials results presented at the Annual Meeting of the American Society of Hematology (ASH) in December 2014, were three significant studies for Hodgkin Lymphoma (HL) patients. The studies, which included early stage studies of two…